Health Insurance · NYSE: MOH
Molina Healthcare earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 4 Feb 2027
Latest: Q3 2026
Molina went live on its $6 billion Florida CMS contract while exiting traditional MAPD and shrinking Marketplace to seven states, narrowing the business around Medicaid and dual-eligible Medicare.
Molina's membership is shrinking in Medicaid and Marketplace, but the business is being reshaped around Medicaid and dual-eligible Medicare. The Florida CMS contract for medically complex children started in the fourth quarter, with about 115,000 members. Management is exiting its traditional Medicare Advantage Prescription Drug (MAPD) product for 2027, and Marketplace is shrinking to seven states. The dual-eligible Medicare business performed well.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $10.5B * |
| Q1 2025 | $11.1B |
| Q2 2025 | $11.4B |
| Q3 2025 | $11.5B |
| Q4 2025 | $11.4B * |
| Q1 2026 | $10.8B |
| Q2 2026 | $10.9B |
| Q3 2026 | $11.1B |
Data
| Q1 2025 | $5.45 |
| Q2 2025 | $4.75 |
| Q3 2025 | $1.51 |
| Q1 2026 | $0.27 |
| Q2 2026 | $1.19 |
| Q3 2026 | $0.73 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 3.6% |
| Q1 2025 | 3.9% |
| Q2 2025 | 3.3% |
| Q3 2025 | 1.2% |
| Q4 2025 | -1.4% |
| Q1 2026 | 0.8% |
| Q2 2026 | 1.3% |
| Q3 2026 | 1.0% |
Data
| Q4 2024 | -$235.0M |
| Q1 2025 | $168.0M |
| Q2 2025 | -$344.0M |
| Q3 2025 | -$163.0M |
| Q4 2025 | -$297.0M |
| Q1 2026 | $1.1B |
| Q2 2026 | -$324.0M |
| Q3 2026 | -$196.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5Bd | $11.1B | $11.4B | $11.5B | $11.4Bd | $10.8B | $10.9B | $11.1B |
| Operating income | $380.0Md | $433.0M | $373.0M | $137.0M | -$162.0Md | $83.0M | $145.0M | $106.0M |
| Operating margin | 3.6% | 3.9% | 3.3% | 1.2% | -1.4% | 0.8% | 1.3% | 1.0% |
| Net income | $251.0Md | $298.0M | $255.0M | $79.0M | -$160.0Md | $14.0M | $60.0M | $38.0M |
| Diluted EPS | — | $5.45 | $4.75 | $1.51 | — | $0.27 | $1.19 | $0.73 |
| Operating cash flow | -$224.0Md | $190.0M | -$302.0Md | -$125.0Md | -$298.0Md | $1.1B | -$294.0Md | -$159.0Md |
| Capital expenditure | $11.0Md | $22.0M | $42.0Md | $38.0Md | -$1.0Md | $27.0M | $30.0Md | $37.0Md |
| Free cash flow | -$235.0M | $168.0M | -$344.0M | -$163.0M | -$297.0M | $1.1B | -$324.0M | -$196.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 22 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 23 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 23 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 10 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 23 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 24 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 24 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 11 Feb 202510-K for the period ended 31 Dec 2024SEC ↗